SEC Filing Analysis: Werewolf Therapeutics, Inc. (HOWL)

Executive Summary

• Trading Significance: Low
• Key Takeaway: MPM Oncology Innovations Fund, L.P. filed a notice of intent to sell 28,657 shares of Werewolf Therapeutics, a transaction with negligible market impact.
• Market Impact: The proposed sale is valued at approximately $37,541, representing about 0.06% of the company's market cap and shares outstanding, indicating a routine portfolio adjustment rather than a significant strategic move.

Company Information

Field	Value
Company	Werewolf Therapeutics, Inc.
Ticker Symbol	HOWL (Note: Not in filing, added for context)
CIK	0001785530
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	MPM Oncology Innovations Fund, L.P.
CIK	0001719960
Title/Position	null
Relationship	Shareholder

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-11-04 (Approximate Sale Date)
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	28,657
Price Per Share	$1.31 (approx.)
Total Value	$37,540.67
Shares Owned After	Not specified
Ownership Type	Not specified

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$37,540.67
% of Market Cap	0.063%
Shares Transacted	28,657
% of Shares Outstanding	0.063%
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a small-cap company with a market capitalization of $60 million, this transaction is de minimis and unlikely to influence market perception or stock price.
• Transaction Significance: The sale represents a tiny fraction of both market capitalization and shares outstanding, falling well below the thresholds for moderate or high significance. It is likely a routine liquidity event for the fund.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction size is too small to have any material impact on the stock's price or trading volume.

Volume & Sentiment

• Expected Volume Impact: Negligible. The number of shares is unlikely to be noticed in daily trading volume.
• Sentiment Indicator: Neutral. The filing does not provide any new information that would shift investor sentiment.

Additional Context

Transaction Notes

• Special Circumstances: The sale is proposed under a Rule 10b5-1 trading plan adopted on September 24, 2025. This indicates the sale was pre-planned and not based on recent material non-public information.